夏冰，主治医师，医学硕士 教育背景： 2003.9—2010.9哈尔滨医科大学临床医学七年制 社会职务： 抗癌协会会员 专业特长： 擅长各类急慢性白血病、恶性淋巴瘤、多发性骨髓瘤、骨髓增生异常综合征(MDS)等疾病的诊治。在临床工作中注重规范化诊疗和实践经验。 学术成就： 承担天津市肿瘤医院院级课题一项，参与自然科学基金，天津市自然科学基金等多项科研课题。发表SCI文章及核心期刊文章十余篇。 发表文章： 1. 夏冰，郭青，赵丹丹，田晨，张翼鷟，吴晓雄。骨髓增生异常综合征中骨髓CD34+、CD34-细胞凋亡和增殖的实验研究。天津医科大学学报2012;18(3):285-288。 2. 夏冰，郭青，赵丹丹，赵海丰，韩晓蘋，王卉，吴晓雄，张翼鷟。骨髓增生异常综合征患者骨髓CD34+和CD34-细胞凋亡与增殖的实验研究及对生存的影响。实验血液学2012;20(6):1392-1397。 3. 夏冰，郭青，赵伟鹏，王晓芳，王亚非，张翼鷟，张连郁。原发肠道的髓细胞肉瘤二例报道及文献复习。2012; 33(10): 869-871。 4. 夏冰，郭青，赵伟鹏，郭姗琦，田晨，张翼鷟。c-Myc在骨髓基质细胞介导的急性髓细胞白血病耐药中作用。中华医学杂志2013; 93(22): 1746 -1749。 5.李晓武，夏冰，郭青，晋鑫，于泳，赵智刚，王晓芳，王亚非，张翼鷟。103例胃黏膜相关淋巴组织淋巴瘤患者的临床特点和预后分析。 6. Bing Xia Xiaowu Li Le Zhang Qing Guo Xin Jin ShanqiGuo Eduardo M. Sotomayor Yizhuo Zhang. BTK inhibitor PCI-32765 targets endogenous and microenvironment-mediated B-cell receptor signaling to supresslymphom cell growth and is highly synergistic with Bortezmib against non-Hodgkin B-cell lymphomas. (ASH Annual Meeting Abstract) Blood 2012; 120: Abstract 4721. 7. Zhang Y Zhao D Zhao H Wu X Zhao W Wang Y Xia B Da W.Hypermethylation of SHP-1 promoter in patient with high-risk myelodysplastic syndrome and it predicts poor prognosis. Medical Oncology. 2012; 29(4):2359-2363. 8. Xin Jin Fang Li ShanqiGuo Bing Xia Ling Zhang Yizhuo Zhang. Arsenic trioxide-induced apoptosis is associated with induction of SHP-1 in human cutaneous T cell lymphoma.(ASH Annual Meeting Abstracts)Blood 2012;120: Abstract 4716. 9. 12.Guo Qing Xia Bing. The role of CXCR4/STAT3/miRNAs in the microenvironment-mediated drug resistance in AML. 2012The first "Chinese Journal of Hematology" Annual Meeting. 10. Li X Xia B Guo S Zhan Z Zhang L Zhao D Wu X Zhang Y. A retrospective ysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components. Ann Hematol. 2013;92(6):807-815。 11. Yizhuo Zhang Qing Guo Dandan Zhao Haifeng Zhao Xiaoxiong Wu Weipeng Zhao Yafei Wang Bing Xia Wanming Da. Expression of CXCR4 is an independent prognostic factor for overall survival and relapse-free survival in patients with myelodysplastic syndrome .Medical oncology 2013;30(1):341. 12. Zhang Y Guo Q Zhao H Zhao D Wu X Zhao W Wang Y Xia B Da W.Expression of CXCR4 is an independent prognostic factor for overall survival and progression-free survival in patients with myelodysplastic syndrome. Medical Oncology. 2013; 30(1):341-346.
